Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?

Detalles Bibliográficos
Autores principales: Bernardi, Marco, Spadafora, Luigi, Galli, Mattia, Biondi-Zoccai, Giuseppe, Sabouret, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074288/
https://www.ncbi.nlm.nih.gov/pubmed/37034516
http://dx.doi.org/10.5114/aoms/160006
_version_ 1785019727929671680
author Bernardi, Marco
Spadafora, Luigi
Galli, Mattia
Biondi-Zoccai, Giuseppe
Sabouret, Pierre
author_facet Bernardi, Marco
Spadafora, Luigi
Galli, Mattia
Biondi-Zoccai, Giuseppe
Sabouret, Pierre
author_sort Bernardi, Marco
collection PubMed
description
format Online
Article
Text
id pubmed-10074288
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-100742882023-04-06 Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients? Bernardi, Marco Spadafora, Luigi Galli, Mattia Biondi-Zoccai, Giuseppe Sabouret, Pierre Arch Med Sci Letter to the Editor Termedia Publishing House 2023-02-03 /pmc/articles/PMC10074288/ /pubmed/37034516 http://dx.doi.org/10.5114/aoms/160006 Text en Copyright: © 2023 Termedia & Banach https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Letter to the Editor
Bernardi, Marco
Spadafora, Luigi
Galli, Mattia
Biondi-Zoccai, Giuseppe
Sabouret, Pierre
Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?
title Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?
title_full Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?
title_fullStr Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?
title_full_unstemmed Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?
title_short Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?
title_sort should sglt2 inhibitors be prescribed in all diabetic type 2 patients?
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074288/
https://www.ncbi.nlm.nih.gov/pubmed/37034516
http://dx.doi.org/10.5114/aoms/160006
work_keys_str_mv AT bernardimarco shouldsglt2inhibitorsbeprescribedinalldiabetictype2patients
AT spadaforaluigi shouldsglt2inhibitorsbeprescribedinalldiabetictype2patients
AT gallimattia shouldsglt2inhibitorsbeprescribedinalldiabetictype2patients
AT biondizoccaigiuseppe shouldsglt2inhibitorsbeprescribedinalldiabetictype2patients
AT sabouretpierre shouldsglt2inhibitorsbeprescribedinalldiabetictype2patients

Ejemplares similares